18 August 2011
Responding to the decision by NICE to recommend only one out of three potential chronic myeloid leukaemia treatments, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
'It is good news that NICE has approved Nilotinib for cancer patients with chronic myeloid leukaemia, however, it is disappointing news for patients that Dasatnib and Imatinib have been rejected. These two drugs could have the potential to improve the quality and length of life for cancer patients.
'Of the two million people living with a cancer diagnosis in the UK over 900,000 (45%) have a rarer cancer  and many of whom still aren’t able to access the drugs they so desperately need. We hope that they and others for rarer cancers turned down by NICE will be put on the priority list of the Government’s Cancer Drugs Fund.'
For more information and support call Macmillan free on 0808 808 00 00 or visit
For further information, please contact:
Julie Wills, Assistant Media & PR Officer, 020 7840 4933
Notes to editors
 Sources: Maddams J, et al. Cancer prevention in the United Kingdom: estimates for 2008. British Journal of Cancer. 2009. 101:541-547.
Rarer cancers are 'other cancers' and exclude the four most common cancers (prostate, colorectal, lung and breast (female) cancers) and non-melanoma skin cancer.
About Macmillan Cancer Support
Macmillan Cancer Support improves the lives of people affected by cancer, providing practical, medical, emotional and financial support. Working alongside people affected by cancer, Macmillan works to improve cancer care. More than one in three of us get cancer. Two million of us are living with it. If you are affected by cancer Macmillan can help.
Every day more people face the toughest fight of their lives. For cancer support every step of the way, or to find out how you can support their work, call Macmillan Cancer Support free on 0808 808 00 00 or find out how we can help